Rockwell Med Inc SEC Filings

Rockwell Medical, Inc. (RMTI) director files initial ownership report with no holdings

A reporting person serving as a director of Rockwell Medical, Inc. has filed a Form 3, which is the initial statement of beneficial ownership of securities. The filing states that no securities are beneficially owned by the reporting person at this time. The form is filed on an individual basis for one reporting person.

The filing also notes that it was submitted late because of administrative delays in obtaining the reporting person’s EDGAR access codes. A power of attorney is referenced, authorizing an attorney-in-fact to sign the form on the reporting person’s behalf.

Rockwell Medical, Inc. (RMTI) director John G. Cooper reported an open-market sale of company stock. On November 18, 2025, he sold 5,079 shares of Rockwell Medical common stock at a price of $0.87 per share, according to this Form 4 filing. After this transaction, Cooper beneficially owns 140,372 shares of Rockwell Medical common stock, held directly.

Rockwell Medical, Inc. reported a change in its Board of Directors. On November 17, 2025, Andrea Heslin Smiley resigned from the Board and its committees, and the company stated that her resignation was not due to any disagreement over operations, policies, or practices.

The Board appointed Joseph H. Dawson, aged 60, as a Class II director effective the same day, to serve until the 2026 Annual Meeting of Stockholders. He will also serve on the Nominating and Corporate Governance Committee.

Under the non-employee director compensation policy, Mr. Dawson will receive an annual cash retainer of $45,000 as a director and $5,000 for serving on the committee, pro-rated through the 2026 Annual Meeting. He was granted an option to purchase 25,000 shares of common stock and 25,000 restricted stock units under the Amended and Restated 2018 Long Term Incentive Plan, with both equity awards vesting on November 17, 2026, subject to continued service.

Rockwell Medical, Inc. (RMTI) furnished an updated corporate presentation under Regulation FD. The presentation, dated November 12, 2025, is provided as Exhibit 99.1 to a Form 8‑K.

The company states the information in this report, including Exhibit 99.1, is furnished and not deemed “filed” under the Exchange Act pursuant to General Instruction B.2. The exhibit list also includes Exhibit 104 for the cover page interactive data file.

Rockwell Medical (RMTI) reported a weaker quarter. Q3 2025 net sales were $15.9 million versus $28.3 million a year ago, driving gross profit of $2.3 million and an operating loss of $1.6 million. Net loss was $1.8 million, or $0.05 per share, compared with net income of $1.7 million last year.

For the first nine months, net sales were $50.9 million versus $76.8 million, with a net loss of $4.8 million. Cash, cash equivalents and available-for-sale investments totaled $23.7 million, and net working capital was $27.9 million; management believes funds are sufficient for at least the next twelve months.

DaVita extended its purchase agreement through December 31, 2025 but is transitioning to another supplier. Rockwell recognized non-refundable payments of $1.7 million year-to-date, including $0.4 million in Q3, and continues to supply DaVita. The company raised $8.0 million gross ($7.8 million net) via its ATM in Q3, with $13.1 million remaining available. Rockwell closed its Greer, South Carolina facility, recording $0.5 million in Q3 and $0.8 million year-to-date in closure costs. Term loan balance was $8.7 million, interest-only through 36 months, with all covenants in compliance. Shares outstanding were 39,405,301 as of September 30, 2025.

Rockwell Medical, Inc. (RMTI) furnished its quarterly results press release. The company reported that it issued a press release announcing financial results for the quarter ended September 30, 2025, and furnished it as Exhibit 99.1 to a Form 8-K.

Consistent with General Instruction B.2, the Item 2.02 information and Exhibit 99.1 are furnished, not filed, and are not incorporated by reference into other filings unless expressly stated. The report was signed by Chief Executive Officer Mark Strobeck.

Insider sale under a trading plan: Senior Vice President and Chief Operating Officer Heather Hunter reported a sale of 2,868 shares of Rockwell Medical, Inc. (RMTI) on 10/01/2025 at a price of $1.19 per share, leaving her with 135,391 shares beneficially owned after the transaction. The filing states the sale was executed under a Rule 10b5-1 trading plan adopted on 12/13/2024, which creates an affirmative defense for scheduled insider trades.

The Form 4 was signed by an attorney-in-fact on 10/08/2025 and includes a remark that the filing is late due to administrative delays obtaining EDGAR codes. No derivative transactions or other non‑derivative purchases were reported on this form.

Heather Hunter, Senior Vice President and Chief Operating Officer of Rockwell Medical, Inc. (RMTI), reported ownership of 138,259 shares of common stock and several option and restricted stock unit grants. The filing lists non-qualified stock options exercisable through 09/09/2032, 03/17/2033, 03/14/2034, and 05/20/2035 with exercise prices of $1.66, $1.37, $1.39, and $1.07, respectively. The report notes RSUs vesting in 2026 and 2027 and discloses the Form 3 was filed late for administrative reasons.

Insider sale under a 10b5-1 plan: Mark Strobeck, President and CEO and a director of Rockwell Medical, sold 6,926 shares of Rockwell Medical common stock on 10/01/2025 at a reported price of $1.19 per share.

After the transaction, the filing reports Mr. Strobeck beneficially owns 330,826 shares, held directly. The sale was executed pursuant to a Rule 10b5-1 trading plan adopted May 30, 2024, and the filer offers to provide details of the number of shares and prices upon request.